efficacy of 153sm-edtmp on bone pain palliation in metastatic patients: breast and prostate cancers

Purpose: this study aimed to evaluate the effect of samarium-153-edtmp (153sm-edtmp) on pain relief bone metastases of breast cancer (bc) and prostate cancer (pc) patients.materials and methods: thirty patients aged 40-77 years (62.6±10.2 years) with intractable metastatic bone pain were included in the current study. a checklist of patient information and a standard questionnaire for the assessment of pain and quality of life were completed before and after four and eight week’s palliative treatment with 37 mbq/kg of 153sm-edtmp. to analyse the data, parametric and non-parametric tests were used in spss softwarresults: twelve females with bc (40%) and 18 males with pc (60%) were included. four and eight weeks after palliative treatment of 153sm-edtmp, the mean pain score reduction and quality of life were statistically increased compared to before the intervention (p-value < 0.05). notably, the amount of pain reduction in the fourth week was more than in the eighth week; however, the quality of life was better in the eighth week, without significant variation (p-value <0.05). in addition, there was no statistically significant relationship between pain reduction and the type of primary diseases, bc, and pc (p-value >0.05).conclusion: the injection of 153sm-edtmp had therapeutic efficacy for bone pain palliation in patients with diffuse bone metastases at the end of the 4th and 8th week post-infusion.